| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.23B | 4.38B | 4.35B | 3.29B | 2.15B | 1.88B |
| Gross Profit | 2.26B | 2.37B | 2.39B | 1.79B | 1.28B | 1.30B |
| EBITDA | 268.00M | 16.00M | -2.00M | 873.00M | 116.00M | 892.00M |
| Net Income | -337.00M | -577.00M | -1.48B | -298.00M | -498.00M | -59.00M |
Balance Sheet | ||||||
| Total Assets | 48.95B | 48.55B | 50.00B | 50.19B | 48.12B | 47.81B |
| Cash, Cash Equivalents and Short-Term Investments | 5.14B | 14.86B | 16.66B | 17.31B | 5.68B | 6.70B |
| Total Debt | 402.00M | 434.00M | 632.00M | 669.00M | 575.00M | 421.00M |
| Total Liabilities | 9.16B | 8.95B | 9.52B | 8.20B | 4.33B | 3.55B |
| Stockholders Equity | 39.76B | 39.58B | 40.75B | 42.10B | 43.41B | 43.78B |
Cash Flow | ||||||
| Free Cash Flow | -293.00M | -735.00M | -1.07B | -652.00M | -1.85B | -620.00M |
| Operating Cash Flow | -60.00M | -430.00M | -850.00M | -143.00M | -775.00M | -215.00M |
| Investing Cash Flow | 460.00M | 2.33B | -2.08B | 2.17B | -2.79B | -244.00M |
| Financing Cash Flow | -216.00M | -216.00M | 160.00M | 14.00M | 617.00M | 1.30B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ¥16.44B | 13.56 | ― | 3.65% | -4.36% | -14.92% | |
69 Neutral | ¥31.34B | 10.06 | ― | 2.78% | 6.72% | 20.01% | |
66 Neutral | ¥81.83B | 21.20 | ― | 2.38% | 4.36% | 79.43% | |
58 Neutral | ¥12.61B | ― | ― | 3.13% | 3.59% | -163.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $38.71B | -35.38 | -49.32% | ― | 45.67% | 29.44% | |
45 Neutral | $39.15B | -114.02 | -0.46% | ― | -4.30% | 82.87% |
CYBERDYNE has been selected for a subsidy under the Japanese government’s program to support Ukraine’s reconstruction. The company will establish a next-generation Cybernics treatment center in Ukraine, partnering with UNBROKEN in Lviv, to aid in the social reintegration of war-affected individuals and restore medical infrastructure.
The most recent analyst rating on (JP:7779) stock is a Hold with a Yen183.00 price target. To see the full list of analyst forecasts on CYBERDYNE stock, see the JP:7779 Stock Forecast page.
CYBERDYNE, INC. reported a decrease in revenue for the three months ending June 30, 2025, with a 13.4% drop compared to the previous year. Despite the revenue decline, the company saw a notable improvement in profits attributable to owners, indicating potential operational efficiencies or cost management strategies. The company did not provide a forecast for the fiscal year ending March 31, 2026, due to uncertainties in its market.
The most recent analyst rating on (JP:7779) stock is a Buy with a Yen365.00 price target. To see the full list of analyst forecasts on CYBERDYNE stock, see the JP:7779 Stock Forecast page.